Atopic Dermatitis Pharmaceutical and Healthcare Pipeline Review H1

Atopic Dermatitis Treatment Pipeline Review H2 2017

PUNE, INDIA, April 21, 2017 / -- The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects.

Get Sample Report @

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
- The report reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Atopic Dermatitis therapeutics and enlists all their major and minor projects
- The report assesses Atopic Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Atopic Dermatitis

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Content: Key Points
Atopic Dermatitis - Companies Involved in Therapeutics Development 36
AbbVie Inc 36
Accolade Pharmaceuticals, LLC 37
AlbireoPharma 38
Almirall, S.A. 39
Amgen Inc. 40
Amorepacific Corporation 41
Anacor Pharmaceuticals, Inc. 42
AnaMar AB 43
AnaptysBio, Inc. 44
AnGes MG, Inc. 45
arGEN-X BV 46
Avexxin AS 47
Blueberry Therapeutics Ltd 48
Brickell Biotech, Inc. 49
Celgene Corporation 50
Cell Medica Limited 51
Cellceutix Corporation 52
ChemoCentryx, Inc. 53
ChironWells GmbH 54
Chugai Pharmaceutical Co., Ltd. 55
Creabilis SA 56
Curapel Limited 57
Dermala Inc 58
Dr. August Wolff GmbH & Co. KG Arzneimittle 59
Eli Lilly and Company 60
F. Hoffmann-La Roche Ltd. 61
Foamix Pharmaceuticals Ltd. 62
Fountain Biopharma Inc. 63
Galapagos NV 64
GlaxoSmithKline Plc 65

Access Report @

Get in touch:

Norah Trent
Wise Guy Consultants Pvt. Ltd.
+1 (339) 368 6938 (US)/+91 841 198 5042 (IND)
email us here